argenx NV ADR is a biotechnology business based in the US. argenx NV ADR shares (ARGX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $594.65 – a decrease of 0.26% over the previous week. argenx NV ADR employs 1,599 staff and has a trailing 12-month revenue of around $2.2 billion.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $594.65 |
|---|---|
| 52-week range | $352.77 - $678.21 |
| 50-day moving average | $607.30 |
| 200-day moving average | $573.79 |
| Wall St. target price | $779.49 |
| PE ratio | 46.7241 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $12.76 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $599.87 from 2025-04-22
| 1 week (2025-04-16) | 2.09% |
|---|---|
| 1 month (2025-03-25) | -0.93% |
| 3 months (2025-01-24) | -7.56% |
| 6 months (2024-10-25) | 7.73% |
| 1 year (2024-04-23) | 59.93% |
|---|---|
| 2 years (2023-04-21) | 54.06% |
| 3 years (2022-04-22) | 92.02% |
| 5 years (2020-04-23) | 317.01% |
Valuing argenx NV ADR stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of argenx NV ADR's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
argenx NV ADR's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 47x. In other words, argenx NV ADR shares trade at around 47x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
| Revenue TTM | $2.2 billion |
|---|---|
| Operating margin TTM | 13.41% |
| Gross profit TTM | $1 billion |
| Return on assets TTM | -0.21% |
| Return on equity TTM | 17.36% |
| Profit margin | 37.05% |
| Book value | $90.49 |
| Market Capitalization | $36.5 billion |
TTM: trailing 12 months
We're not expecting argenx NV ADR to pay a dividend over the next 12 months.
Over the last 12 months, argenx NV ADR's shares have ranged in value from as little as $352.77 up to $678.21. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while argenx NV ADR's is 0.199. This would suggest that argenx NV ADR's shares are less volatile than average (for this exchange).
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren's disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis; empasiprubart for multifocal motor neuropath, CIDP, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy. In addition, the company is also developing ARGX-119, a MuSK agonist to treat congenital myasthenic syndromes and amyotrophic lateral sclerosis; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121 and ARGX 220 that targets the immune system; ARGX-213, which targets FcRn; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic collaborations with OncoVerity, Inc, LEO Pharma A/S, Zai Lab Limited, AbbVie, Inc. , Elektrofi, Genmab SE, Chugai Pharmaceutical Co. , Ltd.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Stock lending allows investors to loan out their existing stocks, although it has both advantages and disadvantages.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.